pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
BioSpace·2h ago·1 min read
save

Experts discuss persistent CMV challenges and new antiviral approaches for transplant patients

Aug 20, 2026·read at BioSpace ↗Neutral

In a recent episode of BioSpace's Denatured podcast, Ian McGowan, chief medical officer of Synklino, and James Hunter, an associate professor of transplantation at Oxford University, joined host Jennifer C. Smith-Parker to talk about cytomegalovirus in transplant care.

The guests described CMV as one of the most stubborn and high-impact infections that can affect patients after organ transplantation, noting its ongoing impact on morbidity and mortality.

The conversation turned to emerging antiviral innovations and the need for better prevention strategies, but no specific drug approvals or clinical trial data were disclosed.

source

This writeup was produced by pharmadog from original reporting by BioSpace.

Original headline: “Rewriting the rules of CMV prevention”

read at BioSpace ↗
278 words · retrieved 2h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 40m agoRegeneron wins FDA approval to challenge Ipsen for rare bone disease marketBioSpace
  • 1h agoUltragenyx bags first gene therapy approval as previously rejected Sanfilippo asset awaits decisionBioSpace
  • 1h agoMerck’s Moderna-partnered vaccine success clears view of post-Keytruda futureBioSpace
  • 6h agoOut of sight, out of work? What’s driving remote job cutsBioSpace
  • 6h ago7 biopharma M&A deals where layoffs followedBioSpace